NCT01612546View on ClinicalTrials.gov

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 15, 2015

Study Completion Date

January 15, 2015

Conditions
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Esophageal CancerRecurrent Gastric CancerSquamous Cell Carcinoma of the EsophagusStage IIIB Esophageal CancerStage IIIB Gastric CancerStage IIIC Esophageal CancerStage IIIC Gastric CancerStage IV Esophageal CancerStage IV Gastric Cancer
Interventions
DRUG

cyclodextrin-based polymer-camptothecin CRLX101

Given IV

OTHER

Laboratory biomarker analysis

Correlative studies

OTHER

Pharmacological studies

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01612546 - Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | Biotech Hunter | Biotech Hunter